Store
IVD Trends and Market Update, November 2022
Publication Date: November 17, 2022
Tags: Coagulation, COVID-19, Genetic Diseases, Hematology, Histology and Cytology, Immunoassay, In Vitro Diagnostics (IVD), Infectious Diseases, Molecular Diagnostics, Oncology and Cancer, Patient Monitoring and Telehealth, Point-of-Care (POC) Testing
Pages: 40
SKU: 22-046
Kalorama Information is excited to present an updated market report on in vitro diagnostics (IVD) products, reflecting the latest insights as of Q3 2022, published in November 2022. This essential report examines the critical factors driving growth and shaping the IVD market in the latter half of 2022.
Report Highlights:
- Market Drivers in Q3 and H2 2022:
- Understanding the key trends influencing market growth during this period.
- Exploring the impact of COVID-19 on the IVD market and its ongoing effects.
- Identifying the major trends affecting the market, including product innovations and new developments.
Key Segments and Trends:
- Emerging Technologies: Focus on next-generation sequencing (NGS), personalized medicine, and mass spectrometry as growing segments capturing industry attention.
- Core Market Interests: Immunochemistry, point-of-care (POC) testing, and molecular diagnostics are highlighted as crucial areas of interest, anticipated to shape the future of IVD.
Market Dynamics:
- Innovation and Development: The IVD market is continuously evolving with new products and technologies, changes in global health spending, regulatory shifts in major markets, and emerging disease trends.
- Demand and Technology Movement: The report covers how the demand for testing and the movement of current and new technologies have demonstrated gains across most areas of the IVD market.
Expert Insights:
- Kalorama Information provides a comprehensive overview of the IVD market, leveraging the extensive experience of its authors and a commitment to presenting the most accurate data available.
- This report is essential for understanding the rapidly changing landscape of the IVD market and staying ahead in this dynamic industry.
Table: Global In Vitro Diagnostic, Sales by Product Segment, 2022 (in millions $)
| Segment | 2022 ($ million) | %Mkt |
| Clinical Chemistry | $XX Million | XX% |
| Immunoassays- non isotopic | ||
| Infectious disease | $XX Million | XX% |
| Other immunos | $XX Million | XX% |
| Blood bank screening | $XX Million | XX% |
| Drugs of Abuse | $XX Million | XX% |
| Diabetes HbA1c, lab | $XX Million | XX% |
| Hematology – Core Lab | $XX Million | XX% |
| Microbiology (ID/AST) | $XX Million | XX% |
| Microbiology (molecular) | $XX Million | XX% |
| Microbiology – Mass Spectrometry | $XX Million | XX% |
| Coagulation (PT/INR) | $XX Million | XX% |
| Coagulation, molecular | $XX Million | XX% |
| D-dimer | $XX Million | XX% |
| Histology/cytology | $XX Million | XX% |
| HPV, molecular | $XX Million | XX% |
| Nucleic acid assays/genetic tests | $XX Million | XX% |
| Blood grouping/typing | $XX Million | XX% |
| Blood bank molecular – NAT Screens | $XX Million | XX% |
| Circulating tumor cells | $XX Million | XX% |
| POC, OTC diabetes | $XX Million | XX% |
| POC, OTC other | $XX Million | XX% |
| POC, professional/hospital | $XX Million | XX% |
| Mass Spectrometry | $XX Million | XX% |
| Other (transplant testing, other, etc.) | $XX Million | XX% |
| IVD Market Total | $XX Million | XX% |
Source: Kalorama Information
For further details and to purchase directly, please contact us.
Table of Contents
Chapter 1: Worldwide IVD Market – November 2022 Update
IVD Market Demand and Growth
- Figure 1-1: Quarter-by-Quarter Segment Performance Commentary, 2022
- Table 1-1: Global In Vitro Diagnostic Sales by Product Market, 2022 ($ million) (Clinical Chemistry; Immunoassays – non isotopic: Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c – lab; Hematology – Core Lab; Microbiology (ID/AST); Microbiology (molecular); Microbiology – Mass Spectrometry; Coagulation (PT/INR); Coagulation, molecular; Histology/cytology; HPV, molecular; Nucleic acid assays; Blood grouping/typing; Blood bank molecular – NAT Screens; Circulating tumor cells; POC, OTC diabetes; POC, OTC other; POC, professional/hospital; Mass Spectrometry; Other IVD)
- Figure 1-2: IVD Segment Performance, Q1 2022 – Q4 2022e ($MN)
- Figure 1-3: IVD Segment Performance, Total Market Value, 2022 ($MN)
COVID-19 Diagnostic Markets
- Table 1-2: COVID-19 Product Sales — Immunoassay (Antigen, Serology), Molecular, Rapid — 2022 ($ millions)
Effect of COVID-19 on Market Segments
- Table 1-3: IVD Market excluding and with COVID-19, 2022
- Figure 1-4: IVD Market Distribution by Segment, 2022
- Figure 1-5: IVD Market by COVID-19 and non-COVID markets, Quarterly Performance, 2022
- Table 1-4: Global In Vitro Diagnostic Market – YoY Growth 2021-2022
- Figure 1-6: Global In Vitro Diagnostic Market – YoY Growth 2021-2022
Chapter 2: Product Trends and New Developments
Selected New – Q3 2022 – Core IVD Product Launches, Developments and Trends
Clinical Chemistry
Flow Cytometry
Immunoassay
Mass Spectrometry
Molecular
Personalized Medicine
POC
Sequencing
Selected COVID-19 Developments – Q3 2022
- Figure 2-1: COVID-19 Test Market by Type, Q1-Q3 2022 – COVID-19 Testing Wanes
Antigen/Antibody
Molecular
Chapter 3: Top IVD Market Participant Results
Selected Competitive Leader Updates
- Figure 3-1: IVD Segment Growth by Leading Competitors, Change in Sales 2021-2022
- Figure 3-2: Changes in Market Distribution for IVD Sales, 2019 – 2022 – Roche and Abbott Battle for #1 Spot
- Figure 3-3: Comparison of Total Diagnostic Sales for Abbott vs Roche 2020-2022 (in millions $)
Q3 M&A Activity
- Table 3-1: IVD-Relevant M&A Activity, 2022
- Figure 3-4: Count of IVD Industry M&A Deals by Month, 2022
Abbott Laboratories
- Table 3-2: Abbott Corporate Summary
Becton Dickinson and Co
- Table 3-3: Becton Dickinson Corporate Summary
bioMérieux SA
- Table 3-4: bioMérieux Corporate Summary
Danaher Corporation
- Table 3-5: Danaher Corporation Summary
Hologic, Inc.
- Table 3-6: Hologic Corporate Summary
QuidelOrtho Corporation
- Table 3-7: QuidelOrtho Corporate Summary
Roche Diagnostic
- Table 3-8: Roche Diagnostic Corporate Summary
Siemens Healthineers
- Table 3-9: Siemens Healthineers Corporate Summary
Sysmex Corporation
- Table 3-10: Sysmex Corporate Summary
Thermo Fisher Scientific
- Table 3-11: Thermo Fisher Scientific Corporate Summary
Chapter 4: New Opportunities
Artificial Intelligence Future Trends
At-Home Testing
Microfluidics in IVD
Telehealth
Related products
Molecular Diagnostics in Oncology, Genetic/Inherited Diseases, and NIPT, 2023-2028
November 29, 2023
In recent decades, genetic technologies for research and diagnostics have transformed healthcare, offering new possibilities in precision medicine and disease management. Next-generation sequencing (NGS) has revolutionized genetic disease diagnostics and oncology, providing comprehensive insights at a relatively low cost. PCR continues to evolve, remaining a central tool in molecular diagnostics. In situ hybridization techniques (ISH)…
Price range: $5,000.00 through $7,500.00
Cell Therapy and Gene Therapy Disease Markets, 2023-2029
April 30, 2024
Explore the future of medicine with our in-depth report on cell therapy, gene therapy, and RNA therapy markets. Cell therapy and gene therapy represent a frontier in modern medicine, promising revolutionary treatments by treating the underlying genetic causes of disease and by genetically controlling the body’s immune system. Recent years have seen an increase in…
Price range: $5,000.00 through $7,875.00
The IVD Market in South Korea, 2024
February 26, 2024
Gain valuable insights into South Korea’s in vitro diagnostics (IVD) market with Kalorama Information’s comprehensive report, The IVD Market in South Korea, 2024. We offer a detailed analysis of South Korea’s IVD revenues for 2023 and forecasts for 2028, segmented into key categories such as clinical chemistry, immunoassay, microbiology/molecular testing, point-of-care (POC),…
Price range: $5,000.00 through $7,875.00
